Hologic, Inc. (HOLX) Stock Analysis — Fair Value, Risk & Moat Rating

Hologic, Inc. (HOLX) stock price is $76.01 as of the latest market close, traded on the NASDAQ exchange.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Hologic, Inc. has a market capitalization of $16.97B, classifying it as a large-cap stock in the Healthcare sector.

Hologic, Inc. operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. It trades on the NASDAQ under the ticker symbol HOLX.

Based on our valuation model, Hologic, Inc. trades 12.7% below our fair value estimate — potentially undervalued.

• FairValueLabs Fair Value: $87.10
• Current Price: $76.01
• Valuation Zone: Buy Zone

Based on 9 Wall Street analysts, the consensus price target for Hologic, Inc. is $76.67, implying upside of 0.9% from the current price.

• Analyst High Target: $78.00
• Analyst Low Target: $76.00

Note: Analyst targets are shown for reference and are not used in our valuation model.

Here are the analyst consensus growth estimates for Hologic, Inc.:

• Revenue growth (current year est.): 3.3%
• EPS growth (current year est.): 4.6%
• Revenue growth (next year est.): 5.3%
• EPS growth (next year est.): 15.4%

The price-to-earnings ratio measures how much investors pay per dollar of earnings:

• Trailing P/E (last 12 months): 31.5x
• Forward P/E (next 12 months est.): 15.7x
• FairValueLabs Fair P/E: 26.8x

Hologic, Inc. has a beta of 0.70, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.

Hologic, Inc.'s balance sheet shows:

• Total Cash: $2.37B
• Total Debt: $2.52B
• Net Cash Position: $-153.7M

A positive net cash position means the company holds more cash than debt, reducing financial risk.

Hologic, Inc. generated $848.6M in trailing twelve-month free cash flow (from $1.10B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.

Hologic, Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.

Hologic, Inc.'s Altman Z-Score is 4.20, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.

Hologic, Inc. scores 2.7/5 stars (Narrow moat · eroding) in our moat analysis:

• ROIC Stability: 3/5
• Gross Margin Trend: 2/5
• Switching Costs: 3/5

A score above 3.5 suggests meaningful pricing power and a defensible market position.

Hologic, Inc.'s return on equity is 10.9%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.

HOLX shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:

1. Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
2. Search for ticker symbol HOLX
3. Place a market or limit order for your desired number of shares

This is not investment advice. Always do your own research before buying any stock.

FairValueLabs classifies Hologic, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.

Earnings per share measures the company's profit allocated to each outstanding share:

• Trailing EPS (last 12 months): $2.41
• Forward EPS (next 12 months est.): $4.86
• Analyst consensus EPS (this year): $4.46
• Analyst consensus EPS (next year): $3.78